Innovative Cellular Therapeutics Holdings, Ltd.

Innovative Cellular Therapeutics Co., Ltd.

Innovative Cellular Therapeutics, Inc.

Shanghai Nuclear Engineering Research & Design Institute

He Sun

Chengfei Pu

Zhiyuan Cao

Lei Xiao

Zhao Wu

Mao Bi

Yu Chen

Li Mao

Wensheng Wang

Yong Wang

Cheng Lu

Wei Shi

Cheng Ye

Mingguang Zheng

Jinquan Yan

Xiaogang Shen

Guoxing Gu

Libing Zhu

Xiankang Dong

Xia Su

Liuhua Shen

The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Chimeric antigen receptor cells for treating solid tumor

The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.

Modified cell expansion and uses thereof

Embodiments relate to a modified T cell comprising an antigen binding molecule, wherein expression and/or function of CDC42 in the modified cell has been enhanced. In embodiments, the modified cell has an increased level of cytokine release in response to an antigen that the antigen binding molecule binds as compared to a corresponding T cell that does not overexpress CDC42. In embodiments, the cytokine release comprises a cytokine release of IFNγ. In embodiments, the modified cell has an enhanced migration capability in response to a chemokine as compared to a corresponding T cell that does not overexpress CDC42.

Modified cell with enhanced migration capability

The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.

Use of chimeric antigen receptor modified cells to treat cancer

Embodiments relate to compositions and methods for treating solid tumors. For example, the compositions comprise modified cells comprising an isolated polynucleotide comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT) promoter operatively associated with a polynucleotide encoding FLT3L.

Activation of APC in immunotherapy

A heat pipe based passive residual heat removal system for a spent fuel pool (). Partitions () are arranged around an inside of the spent fuel pool. Evaporation-end heat pipes () are arranged between the outside of the partitions and an inner wail of the pool. The evaporation-end heat pipes have outlets that extend beyond the pool and are connected to an Inlet of an ascending pipe (), and have inlets connected to an outlet of a descending pipe (). Condensation-end heat pipes () have inlets connected to an outlet of the ascending pipe, and have outlets connected to an inlet of the descending pipe. The heat pipes cool the spent fuel pool. A heat exchange by phase change of working medium in the heat pipe leads to heat exchange of low temperature difference and high efficiency, relying on density difference for natural circulation drive.

Heat pipe based passive residual heat removal system for spent fuel pool

Growing community of inventors

Shanghai, China

He Sun